Prelude Therapeutics (PRLD) Research & Development (2019 - 2026)

Prelude Therapeutics has reported Research & Development for 8 years, with the latest figure at $13.6 million in Q1 2026.

• Quarterly Research & Development fell 52.8% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.1 million (down 33.77% YoY) and the FY2025 annual result came in at $94.3 million, down 20.08% from the prior year.
• Research & Development slipped to $13.6 million in Q1 2026 per PRLD's latest filing, from $18.0 million in the prior quarter.
• Over five years, Research & Development peaked at $31.6 million in Q4 2024 and troughed at $13.6 million in Q1 2026.
• A 5-year average of $24.8 million and a median of $25.8 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2026: Research & Development surged 38.56% in 2022, then plunged 52.8% in 2026.
• Over 5 years, Research & Development stood at $25.9 million in 2022, then grew by 17.25% to $30.3 million in 2023, then gained by 4.25% to $31.6 million in 2024, then tumbled by 43.1% to $18.0 million in 2025, then declined by 24.41% to $13.6 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $13.6 million, $18.0 million, and $21.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.